Humana Inc. (NYSE:HUM) Shares Sold by Glenview Trust co

Glenview Trust co decreased its holdings in Humana Inc. (NYSE:HUM - Free Report) by 8.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 37,110 shares of the insurance provider's stock after selling 3,415 shares during the quarter. Glenview Trust co's holdings in Humana were worth $9,415,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Pinnacle Wealth Management Advisory Group LLC boosted its position in Humana by 3.6% in the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider's stock valued at $272,000 after buying an additional 37 shares during the period. Atlas Brown Inc. raised its stake in shares of Humana by 0.6% in the fourth quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider's stock valued at $1,611,000 after acquiring an additional 38 shares in the last quarter. Moors & Cabot Inc. boosted its holdings in Humana by 2.5% in the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider's stock valued at $519,000 after purchasing an additional 40 shares during the period. Mather Group LLC. grew its stake in Humana by 21.0% during the 4th quarter. Mather Group LLC. now owns 236 shares of the insurance provider's stock worth $60,000 after purchasing an additional 41 shares in the last quarter. Finally, Capital Advisors Ltd. LLC increased its holdings in Humana by 26.1% during the 4th quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider's stock worth $53,000 after purchasing an additional 43 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.

Remove Ads

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the business's stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company's stock, valued at approximately $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.37% of the stock is owned by company insiders.

Humana Stock Performance

Shares of HUM stock traded down $0.72 during trading hours on Thursday, hitting $266.62. The stock had a trading volume of 1,069,934 shares, compared to its average volume of 1,712,095. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market capitalization of $32.18 billion, a PE ratio of 26.80, a PEG ratio of 2.05 and a beta of 0.57. The stock's 50 day moving average is $271.43 and its 200 day moving average is $278.21. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts' consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, research analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.33%. The ex-dividend date of this dividend is Friday, March 28th. Humana's dividend payout ratio (DPR) is presently 35.58%.

Analyst Ratings Changes

HUM has been the subject of several recent research reports. Piper Sandler lifted their price objective on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research note on Wednesday, January 15th. Truist Financial lifted their price target on shares of Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a research note on Monday, January 6th. StockNews.com cut shares of Humana from a "buy" rating to a "hold" rating in a report on Tuesday. JPMorgan Chase & Co. reduced their price objective on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a report on Tuesday, February 18th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. Nineteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $285.68.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.